5.2
Patients with psoriatic disease who become infected with SARS-CoV-2 should be prescribed and adhere to evidence-based COVID-19 therapies. Evidence-based therapies* currently include supportive care for all patients with consideration of the following:
For outpatients:
• Bamlanivimab and Etesevimab to be administered together for patients meeting specific criteria and who are at high risk for progressing to severe COVID-19 and/or hospitalization
• Casirivimab and imdevimab to be administered together for patients meeting specific criteria and who are at high risk for progressing to severe COVID-19 and/or hospitalization
For hospitalized patients:
• Dexamethasone (systemic steroids) for patients meeting specific criteria
• Remdesivir treatment for patients meeting specific criteria
• Baricitinib, in combination with remdesivir, for patients meeting specific criteria
• Tocilizumab, in combination with dexamethasone, for patients meeting specific criteria
The care of the hospitalized patient should include consultation with rheumatologists, dermatologists, and/or infectious disease specialists as medically necessary.
* Evidence based therapies are those that have been tested in well-conducted randomized controlled clinical trials, and have proven benefit on clinically relevant COVID-19 outcomes.